IDEAYA Biosciences Enrolls First Patient In Phase 1 Dose Escalation Trial Of IDE574 For Multiple Solid Tumors
Benzinga Newsdesk 7 months ago
BiotechHealth CareGeneral
Potential first-in-class and selective equipotent dual inhibitor of KAT6/7 with single-digit to low teens nano-molar cellular potency in target engagement assays against KAT6 and KAT7, and ~350-to-2,000-fold selectivity
- Potential first-in-class and selective equipotent dual inhibitor of KAT6/7 with single-digit to low teens nano-molar cellular potency in target engagement assays against KAT6 and KAT7, and ~350-to-2,000-fold selectivity over the KAT5 and KAT8 paralogs
- KAT6/7 dual inhibitor demonstrates greater monotherapy efficacy and durability than KAT6 selective inhibitors in preclinical CDX and PDX models
- Multiple combination opportunities with IDE574 and IDEAYA's proprietary pipeline
- Potential first-in-class and best-in-class preclinical profile will be presented at AACR 2026